The number and volume of pharmaceutical companies’ mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation.
Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.
Table of Contents
1. INTRODUCTION
2. THEORETICAL FRAMEWORK AND INDUSTRY
2.1. OVERVIEW OF M&A THEORY AND THE PHARMACEUTICAL INDUSTRY
2.2. REVIEW OF R&D AND THE DRUG APPROVAL PROCESS
3. EMPIRICAL ANALYSES
3.1. EMPIRICAL SPECIFICATION AND DATA
3.1.1. EMPIRICAL SPECIFICATION
3.1.2. DATA
3.2. RESULTS - MERGERS & ACQUISITIONS AND R&D INTENSITY
3.3. MERGERS & ACQUISITIONS AND R&D EFFICIENCY
4. SMALL ACQUISITIONS AND THEIR IMPACT ON INDUSTRY EFFICIENCY
5. DISCUSSION, LIMITATIONS AND FOOD FOR THOUGHT
Research Objectives and Core Themes
This thesis investigates the impact of Mergers & Acquisitions (M&A) on the Research & Development (R&D) productivity of pharmaceutical companies, specifically examining whether such deals effectively refill drug pipelines or hinder innovation capacity. The research seeks to determine if major pharmaceutical firms should prioritize large-scale mergers or internal R&D investment to drive long-term growth and industry performance.
- The influence of M&A activity on R&D intensity and firm-level efficiency.
- The comparative role of large-scale "megamergers" versus small acquisitions in fostering innovation.
- Differences in drug development regulation and approval processes across key global regions.
- Analysis of factors contributing to the decline in pharmaceutical R&D productivity, such as regulatory hurdles and rising development costs.
- The potential transition of the pharmaceutical industry towards a two-tier structure of research-focused versus marketing-focused entities.
Excerpt from the Book
2.1. OVERVIEW OF M&A THEORY AND THE PHARMACEUTICAL INDUSTRY
A tremendous amount of M&A’s occurred during the last decades. Between 1997 and 2007 alone, the global M&A deal value exceeded US$ 29 trillion (Financier Worldwide, 2008). The outcomes of many of these M&A transactions have been ambiguous, as short-term event studies show little shareholder value creation overall. Target companies, however, gain significantly whereas acquirers mostly lose shareholder value. This raises the question why companies undertake acquisitions in the first place. According to Sudarsanam, who summarizes existing research about the major motivations for horizontal mergers, economies of scale and scope, new growth opportunities, market power and network externalities incite companies to seek M&As (cf. Sudarsanam, 2010: 123–151). But these considerations do not explain the waves in which mergers occur, between 1900 and 2010 six waves arose. In order to understand these waves, additional decision factors for M&A activity, such as hubris and other behavioral biases as well as interdependencies between firms (e.g. bandwagon effect, mini-max regret theory), have been investigated. Furthermore, external shocks can cause acquisitions (cf. Powell & Yawson, 2005). Examples are the airline deregulation or technological advances in information technology, causing excess capacity which in turn leads to industry consolidation.
Summary of Chapters
1. INTRODUCTION: Outlines the rise in pharmaceutical M&A activity and establishes the research goal of evaluating the impact of these mergers on R&D intensity and efficiency.
2. THEORETICAL FRAMEWORK AND INDUSTRY: Provides a theoretical overview of M&A motivations and a detailed examination of the pharmaceutical R&D and drug approval processes.
3. EMPIRICAL ANALYSES: Presents the econometric methodology, dataset, and results concerning the impact of mergers on R&D intensity, revenue growth, and R&D efficiency.
4. SMALL ACQUISITIONS AND THEIR IMPACT ON INDUSTRY EFFICIENCY: Discusses the role of small and medium-sized firms and whether smaller acquisitions can counteract the efficiency loss observed in large-scale mergers.
5. DISCUSSION, LIMITATIONS AND FOOD FOR THOUGHT: Synthesizes the empirical findings, addresses limitations, and proposes future policy implications, including a potential shift toward a two-tier industry structure.
Keywords
Pharmaceutical Industry, Mergers & Acquisitions, R&D Intensity, R&D Efficiency, Drug Innovation, Megamergers, Patent Expiration, Drug Approval Process, Regulatory Impact, Small Acquisitions, Research Productivity, Industry Consolidation, Innovation Policy, Biotechnology, Pharmaceutical Economics
Frequently Asked Questions
What is the core focus of this thesis?
The thesis examines the impact of pharmaceutical mergers and acquisitions on the R&D intensity and efficiency of the acquiring companies and the industry as a whole.
What are the central themes discussed in the work?
The work explores M&A motivations, the intricacies of the pharmaceutical R&D pipeline, the impact of regulatory environments on innovation, and the potential benefits of small acquisitions over large-scale mergers.
What is the primary research question?
The main question is whether large pharmaceutical mergers actually increase R&D intensity and efficiency to boost innovation, or if they act as a detriment to the long-term drug development pipeline.
Which methodology is employed in this research?
The author uses an empirical analysis based on a newly constructed dataset of major pharmaceutical mergers between 1980 and 2010, applying econometric random effects models to test the impact of mergers on R&D metrics.
What is covered in the main body of the text?
The main body covers theoretical frameworks, a comparative analysis of drug regulation in different countries (US, Japan, Germany, Switzerland), and empirical tests of how mergers and megamergers correlate with R&D spending and output (New Drug Applications).
Which keywords best describe this study?
Key terms include Pharmaceutical Industry, Mergers & Acquisitions, R&D Efficiency, Drug Innovation, and Research Productivity.
How do large mergers impact R&D intensity according to the results?
The findings suggest that large mergers, particularly megamergers, are followed by a decline in R&D intensity, often as companies divert resources to cover debt or manage integration complexities.
What is the author's suggestion regarding the future of the pharmaceutical industry?
The author suggests a potential shift toward a two-tier industry structure, where specialized research organizations conduct development and larger companies focus on marketing and production.
What role do small acquisitions play?
Small acquisitions are viewed as potentially beneficial mechanisms that allow large companies to access innovative technology and external drug pipelines without the heavy integration costs associated with large mergers.
- Quote paper
- Jan Schmidt (Author), 2013, Do Pharmaceutical Mergers Harm Drug Innovation?, Munich, GRIN Verlag, https://www.grin.com/document/299729
